Jin-Lin Hou
Overview
Explore the profile of Jin-Lin Hou including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
131
Citations
1564
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chen L, Wu T, Fan R, Qian Y, Liu J, Bai J, et al.
EBioMedicine
. 2024 Jan;
100:104962.
PMID: 38184937
Background: Liver cirrhosis (LC) is the highest risk factor for hepatocellular carcinoma (HCC) development worldwide. The efficacy of the guideline-recommended surveillance methods for patients with LC remains unpromising. Methods: A...
2.
Hao X, Fan R, Zeng H, Hou J
J Clin Transl Hepatol
. 2024 Jan;
11(7):1508-1519.
PMID: 38161501
Hepatocellular carcinoma (HCC) accounts for the majority of primary liver cancers and represents a global health challenge. Liver cancer ranks third in cancer-related mortality with 830,000 deaths and sixth in...
3.
Guo P, Zuo J, Huang K, Lai G, Zhang X, An J, et al.
Zool Res
. 2023 Mar;
44(3):451-466.
PMID: 36994536
Chronic liver injury leads to progressive liver fibrosis and ultimately cirrhosis, a major cause of morbidity and mortality worldwide. However, there are currently no effective anti-fibrotic therapies available, especially for...
4.
Wu T, Fan R, Bai J, Yang Z, Qian Y, Du L, et al.
J Hematol Oncol
. 2023 Jan;
16(1):1.
PMID: 36600307
Background: Hepatocellular carcinoma (HCC) generally arises from a background of liver cirrhosis (LC). Patients with cirrhosis and suspected HCC are recommended to undergo serum biomarker tests and imaging diagnostic evaluation....
5.
Lau G, Yu M, Wong G, Thompson A, Ghazinian H, Hou J, et al.
Hepatol Int
. 2022 Jan;
16(2):486-487.
PMID: 35076895
No abstract available.
6.
Lau G, Yu M, Wong G, Thompson A, Ghazinian H, Hou J, et al.
Hepatol Int
. 2021 Aug;
15(5):1031-1048.
PMID: 34427860
Background & Aim: Hepatitis B reactivation related to the use of immunosuppressive therapy remains a major cause of liver-related morbidity and mortality in hepatitis B endemic Asia-Pacific region. This clinical...
7.
Zheng B, Liu X, Fan R, Bai J, Wen H, Du L, et al.
Clin Cancer Res
. 2021 May;
27(13):3772-3783.
PMID: 33947693
Purpose: Intratumoral hepatitis B virus (HBV) integrations and mutations are related to hepatocellular carcinoma (HCC) progression. Circulating cell-free DNA (cfDNA) has shown itself as a powerful noninvasive biomarker for cancer....
8.
Chen L, Abou-Alfa G, Zheng B, Liu J, Bai J, Du L, et al.
Cell Res
. 2021 Feb;
31(5):589-592.
PMID: 33589745
No abstract available.
9.
Yin X, Liu Z, Liu J, Liu Y, Xie L, Tao L, et al.
Chin Med J (Engl)
. 2019 Oct;
132(19):2315-2324.
PMID: 31567376
Background: Nucleos(t)ide analog (NA) in combination with peginterferon (PegIFN) therapy in patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) shows better effectiveness than NA monotherapy in hepatitis...
10.
Xiao L, Zhou Z, Li W, Peng J, Sun Q, Zhu H, et al.
Aging (Albany NY)
. 2019 Sep;
11(17):7123-7149.
PMID: 31495785
Polycomb group (PcG) proteins have recently been identified as critical regulators in tumor initiation and development. However, the function of CBX8 in human hepatocellular carcinoma (HCC) remains largely unknown. Our...